104 related articles for article (PubMed ID: 37028561)
1. Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.
Filippatos F; Tatsi EB; Papagiannopoulos C; Syriopoulou V; Michos A
J Virol Methods; 2023 Jun; 316():114728. PubMed ID: 37028561
[TBL] [Abstract][Full Text] [Related]
2. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1
Michos A; Tatsi EB; Filippatos F; Dellis C; Koukou D; Efthymiou V; Kastrinelli E; Mantzou A; Syriopoulou V
Vaccine; 2021 Sep; 39(40):5963-5967. PubMed ID: 34400017
[TBL] [Abstract][Full Text] [Related]
3. Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay.
Mousa ZS; Abdulamir AS
Arch Razi Inst; 2022 Feb; 77(1):391-402. PubMed ID: 35891753
[TBL] [Abstract][Full Text] [Related]
4. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
5. Development of ELISA-Based Assay for Detection of SARS-CoV-2 Neutralizing Antibody.
Mishra KP; Singh M; Saraswat D; Singh S
Viral Immunol; 2023 Oct; 36(8):495-502. PubMed ID: 37643285
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
7. Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody.
Duan X; Shi Y; Zhang X; Ge X; Fan R; Guo J; Li Y; Li G; Ding Y; Osman RA; Jiang W; Sun J; Luan X; Zhang G
Biosens Bioelectron; 2022 Mar; 199():113883. PubMed ID: 34942543
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein.
Pereira de Jesus BA; Gomes AA; Clark AE; Rodrigues TA; Ledgerwood-Lee M; Van Zant W; Brickner H; Wang M; Blum DL; Cassera MB; Carlin AF; Aronoff-Spencer ES; da Silva GF; Magalhães MLB; Ray P
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560827
[TBL] [Abstract][Full Text] [Related]
9. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
10. Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity.
Filippatos F; Tatsi EB; Efthymiou V; Syriopoulou V; Michos A
J Biol Rhythms; 2022 Oct; 37(5):562-566. PubMed ID: 35730571
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
12. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
14. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
15. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
16. The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody.
Li Y; He J; Zhang Y; Liang D; Zhang J; Ji R; Wu Y; Su Z; Ke C; Xu N; Tang Y; Xu J
Front Cell Infect Microbiol; 2023; 13():1203625. PubMed ID: 37736103
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
[TBL] [Abstract][Full Text] [Related]
18. Presence of neutralizing SARS-CoV-2 antibodies in asymptomatic population of N'Djamena, Chad.
Wondeu ALD; Abakar MF; Frasca F; Nodjikouambaye AZ; Abdelrazakh F; Naibei N; Dzomo GRT; Djimtoibaye D; Mad-Toingue J; Scagnolari C; Antonelli G; Linardos G; Russo C; Perno CF; Yandai FH; Atturo S; Hiscott J; Colizzi V; Cappelli G; Ngueadoum N; Haroun A; Choua O; Moussa AM
Immun Inflamm Dis; 2024 Jan; 12(1):e1154. PubMed ID: 38270301
[TBL] [Abstract][Full Text] [Related]
19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
20. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
